REG - Nanosynth Group PLC - Strategy Update

NanosynthAnnouncement

01/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220601:nRSA4564Na&default-theme=true

RNS Number : 4564N  Nanosynth Group PLC  01 June 2022

 

1 June 2022

 

nanosynth group plc

("nanosynth", the "Company" or the "Group")

Strategy Update

nanosynth, the AIM quoted company specialising in the synthesis and
application of nanoparticles to create new and improve existing products,
announces that the Company has conducted a strategic review and, based on
recent research and development undertaken, it has identified seven new
verticals in which the Company intends to focus on licensing its nanoparticle
technology.

The verticals and areas in which the Company will be focussing are based on
significant market research and feedback from potential customers.  They
include:

1. Animal Heath & Wellbeing (improved bioavailability / uptake of dietary
minerals and vitamins)

1.   Ruminant supplements - sheep and cattle (dairy and beef)

2.   Monogastric supplements - pigs and chickens

3.   Piglets - veterinarian treatments

4.   Insects - enriched protean (animal feed and human)

5.   Snails - protein, caviar and mucin (cosmetic ingredient)

6.   Companion animals - enriched pet food and veterinarian treatments

7.   Equine - enhanced fertility and performance (pre and post exercise)

2. Cosmetics

1.   Sunscreen - mineral based sun protection

2.   Hair Care - dermatological treatment

3.   Pigments - makeup

3. Medical

1.   Vitamin supplements - enhance biocapacity / uptake and performance
(tablets, gels, etc)

2.   Medical supplements - treatment of acute deficiencies (intravenous -
bags and injections)

3.   Lateral flow testing - used to produce the indicator "line"

4.   Topological treatments - delivery though the skin (e.g. pain relief,
muscle recovery, and treatment of skin cancer via localised hyperthermia)

5.   Medical imaging - contrast agents in CT and MRI scanners to show up
cancer tumours, brain aneurisms etc

6.   Chemotherapy - cancer treatments (e.g. Glioblastoma / brain tumour)

7.   Targeted drug delivery - onsite delivery of the drug to the site of
action (e.g. cancer tumour thereby reducing side effects)

8.   Cataracts nonsurgical treatment and prevention -  via antiglycation
can be delivered as eye drops, injection or part of a contact lens

4. Plants

1.   Fertilizer - improved yields, shorter harvests and higher nutritional
value for commercial farming (crops, ornamental and medical)

2.   Seed coating - improved germination and enhanced vigour for commercial
farming

3.   Domestic plant food - improved yields, shorter harvests and higher
nutritional value

4.   Citrus Greening treatment and prevention - biocide for commercial
farming

5.   Xylella treatment and prevention - biocide treatment for commercial
farming

6.   Verticillium treatment and prevention - biocide treatment for
commercial farming

5. Food & Drink  (improved bioavailability / uptake of dietary minerals
and vitamins)

1.   Breakfast cereals - enriched nutrients

2.   Fortified flour - enriched nutrients

3.   Baked products - enriched nutrients (e.g. bread, biscuits etc)

4.   Pasta - enriched nutrients

5.   Hot beverages - enriched nutritional value (e.g. iron)

6.   Sports nutrition - pre and post exercise

6. Functional Coatings

1.   Antipathogenic Respirators - follows on from the face masks and air
filtration (for example gas masks and medical filters)

2.   Functional Paints - e.g. antiviral and antibacterial additives,
catalytic breakdown of pollutants (e.g. formaldehyde)

3.   Antipathogenic coatings - added into plastics (e.g. laminated wood,
door handles, automotive parts, storage containers) and textiles (e.g.
clothing, hazmat suit, soft furnishings, bedding)

4.   Catalytic converters - for the automotive industry

7. Electronics

1.   LED Phosphors - to fine tune the wavelength emission of the light

2.   Semiconductors - e.g. printable electronics, quantum dots

3.   Batteries - including printable batteries

 

The 37 Research & Development projects in the identified vertical markets
have all been packaged into individual business cases.  The Company's lawyers
are currently  ensuring that the appropriate patents are applied for in each
of the seven vertical markets and business development initiatives with
clients that have expressed significant interest are being pursued. The
Company is planning to offer an opportunity to partner on the individual
projects, while retaining its core patented technology, enabling the clients
to enhance their IP through the partnership. The Company plans to cover the
commercial cost through the development phase through a model whereby the
partnering client is charged for development work packages. The Company's
commercial strategy will be to take either a royalty on the product sold by
the partnering client or the Company will supply relevant nano material to the
client for the project on an exclusive basis.

There can be no certainty at this stage that any of the discussions will
result in partnerships on any of the individual projects however the Company
is actively seeking to progress these opportunities and will provide further
updates to the market as appropriate.

Mark Duffin, Chief Executive of nanosynth, commented: "As a Company, we are
extremely excited about the significant market sectors that have expressed an
interest in adopting our technology which is expected to take us from a
licensing business model into the development, production and supply of
nanoparticles."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 ('MAR') which has been incorporated into UK law by
the European Union (Withdrawal) Act 2018.  Upon the publication of this
announcement via Regulatory Information Service ('RIS'), this inside is now
considered to be in the public domain.

 

ENQUIRIES:

 nanosynth group plc                                              via IFC Advisory

 Mark Duffin (Chief Executive Officer)

 SP Angel Corporate Finance LLP                                   +44 20 3470 0470

 Nominated Adviser and Broker

 Stuart Gledhill

 Caroline Rowe

 IFC Advisory Ltd                                                 +44 20 3934 6630

 Graham Herring

 Zach Cohen

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFLFSEELILVIF